European Patient Innovation Summit publishes a position paper on Digital Health from a Patient Perspective with recommendations on digital health.

On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.

From January 13-16 2020, Novartis attended the J.P Morgan Healthcare Conference in San Francisco.

EPIS participants call for all stakeholders to ensure the patient voice is at the heart of the development of digital health solutions

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today.

Novartis joins seven global companies to found the Value Balancing Alliance

COVID-19 is disrupting Africa’s health services – potentially undermining decades of progress on child health.

The Corporate Reputation of Pharma 2019 global report reflects the findings of a survey conducted by PatientView with patient organizations worldwide.